Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT

Lupus

Volumn 23, Issue 8, 2014, Pages 743-751

  Conti, F ^a   Perricone, C ^a   Reboldi, G ^b   Gawlicki, M ^c   Bartosiewicz, I ^a   Pacucci, V A ^a   Massaro, L ^a   Miranda, F ^a   Truglia, S ^a   Alessandri, C ^a   Spinelli, F R ^a   Teh, L S ^d   Ceccarelli, F ^a   Valesini, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Linguistic Validation   (United States)

^d ROYAL BLACKBURN HOSPITAL   (United Kingdom)

Author keywords

Autoantibodies; Autoimmunity; Lupus; LupusQoL; Quality of life; SF 36; Systemic lupus erythematosus

Indexed keywords

ADULT; ARTICLE; CONVERGENT VALIDITY; DISCRIMINANT VALIDITY; DISEASE ACTIVITY; DISEASE DURATION; FATIGUE; FEMALE; HEALTH CARE PLANNING; HUMAN; INTERNAL CONSISTENCY; LUPUS QUALITY OF LIFE; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 36; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS INTERNATIONAL COLLABORATING CLINICS AMERICAN COLLEGE RHEUMATOLOGY DAMAGE INDEX SCORE; TEST RETEST RELIABILITY; VALIDATION STUDY; ITALY; LUPUS ERYTHEMATOSUS, SYSTEMIC; QUESTIONNAIRE;

ADULT; FEMALE; HUMANS; ITALY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES;

EID: 84903538406     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314524466     Document Type: Article

References (29)

1. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 1997; 24: 1061-1065.
2. Conti F, Perricone C, Ceccarelli F, Valesini G. Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: Two sides of the same coin. Autoimmun Rev 2010; 9: 716-720.
3. Bertsias GK, Ioannidis JP, Boletis J, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: Literature based evidence for the selection of endpoints. Ann Rheum Dis 2009; 68: 477-483.
4. Conti F, Ceccarelli F, Perricone C, et al. Flare, persistently active disease, and serologically active clinically quiescent disease in systemic lupus erythematosus: A 2-year follow-up study. PLoS One 2012; 7: e45934.
5. Felce D, Perry J. Quality of life: Its definition and measurement. Res Dev Disabil 1995; 16: 51-74.
6. Lam GK, Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 2005; 23: S120-S132. (Pubitemid 46657518)
7. Diniz DP, Schor N. Qualidade de vida. Série guias de medicina ambulatorial e hospitalar - UNIFESP - Escola Paulista de Medicina. Barueri: Manole, 2006.
8. Hanly JG. Disease activity, cumulative damage and quality of life in systematic lupus erythematosus: Results of a cross-sectional study. Lupus 1997; 6: 243-247.
9. Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976) 2000; 25: 3130-3139.
10. Ware JE Jr. The status of health assessment 1994. Annu Rev Public Health 1995; 16: 327-354.
11. McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus 2006; 15: 633-643.
12. Thumboo J, Fong KY, Ng TP, Leong KH, Feng PH, Boey ML. Initial construct cross-cultural validation of the Short Form for quality of life assessment of systemic lupus erythematosus patients in Singapore. Ann Acad Med Singapore 1997; 26: 282-284.
13. McElhone K, Abbott J, Shelmerdine J, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. Arthritis Rheum 2007; 57: 972-979.
14. Jolly M, Pickard AS, Wilke C, et al. Lupus-specific health outcome measure for US patients: The LupusQoL-US version. Ann Rheum Dis 2010; 69: 29-33.
15. Touma Z, Gladman DD, Ibañez D, Urowitz MB. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol 2011; 38: 1898-1905.
16. Devilliers H, Amoura Z, Besancenot JF, et al. LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2012; 51: 1906-1915.
17. González-Rodríguez V, Peralta-Ramírez MI, Navarrete-Navarrete N, Callejas-Rubio JL, Santos Ruiz AM, Khamashta M. Adaptation and validation of the Spanish version of a diseasespecific quality of life measure in patients with systemic lupus erythematosus: The Lupus quality of life [article in Spanish]. Med Clin (Barc) 2010; 134: 13-16.
18. Wang SL, Wu B, Leng L, Bucala R, Lu LJ. Validity of LupusQoLChina for the assessment of health related quality of life in Chinese patients with systemic lupus erythematosus. PLoS One 2013; 8: e63795.
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
20. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737-1740.
21. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-664.
22. Isenberg D, Ramsey-Goldman R. Systemic Lupus International Collaborating Group - onwards and upwards? Lupus 2006; 15: 606-607.
23. Kaiser H. The application of electronic computers to factor analysis. Educ Psychol Meas 1960; 20: 141-151.
24. Horn JL. A rationale and test for the number of factors in factor analysis. Psychometrika 1965; 30: 179-185.
25. Cattell RB, Vogelmann S. A comprehensive trial of the scree and kg criteria for determining the number of factors. Multivariate Behav Res 1977; 12: 289-325.
26. Yee CS, Farewell VT, Isenberg DA, et al. The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) 2011; 50: 982-988.
27. Conti F, Alessandri C, Perricone C, et al. Neurocognitive dysfunction in systemic lupus erythematosus: Association with antiphospholipid antibodies, disease activity and chronic damage. PLoS One 2012; 7: e33824.
28. Yee CS, McElhone K, Teh LS, Gordon C. Assessment of disease activity and quality of life in systemic lupus erythematosus - New aspects. Best Pract Res Clin Rheumatol 2009; 23: 457-467.
29. Petri M. Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2002; 16: 847-858.